Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s shares rose by 15.64% in Friday’s trading


Dallas, Texas 11/18/2013 (Financialstrend) – In Friday’s trading session, Idera Pharmaceuticals Inc (NASDAQ:IDRA) rose by 15.64 %. The shares opened at a price of $1.80, which touched the intraday high of $2.25 and headed to a close of $2.07. Around 2.35 million exchanged hands over the trading day and an average volume of 1.41 million shares were traded over a 30 day period. The 52-week low of Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares is $0.19 and its 52-week high is $3.12. The company has a market capitalization of $96.72 million.                                          

About the company

Idera Pharmaceuticals Inc (NASDAQ:IDRA) is a clinical-stage bio-technology company that is involved in the discovery & development of novel synthetic-deoxyribonucleic acid &  ribonucleic acid – based drug candidates. It is developing drug-candidates that are specifically designed to modulate the immune responses that are mediated via Toll-like Receptors. Idera Pharmaceuticals Inc (NASDAQ:IDRA) is also evaluating gene-silencing oligonucleotides. These inhibit production of disease-associated-proteins by targeting the RNA.

In the year that  ended 31 December 2011, Idera Pharmaceuticals Inc (NASDAQ:IDRA) also had a collaboration with Merck Sharp & Dohme, for the use of various agonists of TLRs 7, 8 & 9 as vaccine-adjuvants for cancer, infectious-diseases, & Alzheimer’s disease. In 2011 November Idera Pharmaceuticals Inc (NASDAQ:IDRA) reacquired the rights for IMO-2055 from Merck KGaA, Darmstadt. This was the company’s former collaborator.

Idera Pharmaceuticals Inc (NASDAQ:IDRA) has created different DNA-based compounds. In preclinical studies, these act as antagonists of TLR7 &TLR9, like IMO-3100, or as the antagonists of TLRs 7, 8, &  9, like IMO-8400. Idera Pharmaceuticals Inc (NASDAQ:IDRA) is developing IMO-3100. This is an antagonist of TLR7 & TLR9, for treating psoriasis. The company  has chosen IMO-8400, and the antagonist of TLRs 7, 8, & 9, for development in treating autoimmune diseases. In this lupus is the initial disease indication. IMO-2055- which is a  TLR9 agonist, is the company’s lead drug candidate that is used to treat cancer.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.